These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16680993)
1. Stopping the practice of authorized generics: Mylan's effort to close the gaping black hole in the Hatch-Waxman act. Porter B J Contemp Health Law Policy; 2005; 22(1):177-209. PubMed ID: 16680993 [No Abstract] [Full Text] [Related]
2. India's generics-only drug policy could put health at risk. Gourd E Lancet Oncol; 2017 Jul; 18(7):e373. PubMed ID: 28583793 [No Abstract] [Full Text] [Related]
4. FDA targets unapproved drugs. Young D Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170 [No Abstract] [Full Text] [Related]
5. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era? Kesselheim AS; Darrow JJ Yale J Health Policy Law Ethics; 2015; 15(2):293-347. PubMed ID: 26333236 [TBL] [Abstract][Full Text] [Related]
6. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond. Kelly C Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856 [TBL] [Abstract][Full Text] [Related]
7. Contradictory actions on off-label use of prescription drugs? The FDA and CMS versus the U.S. Justice Department. Curtiss FR; Fairman KA J Manag Care Pharm; 2009 Mar; 15(2):161-5. PubMed ID: 19236131 [No Abstract] [Full Text] [Related]
8. US governors seek to limit opioid prescribing. Dyer O BMJ; 2016 Feb; 352():i1144. PubMed ID: 26912533 [No Abstract] [Full Text] [Related]
9. No cancer patient has to live in pain, but many still do. McNeil C J Natl Cancer Inst; 1997 Sep; 89(17):1250-2. PubMed ID: 9293910 [No Abstract] [Full Text] [Related]
11. BIOSIMILAR DRUGS ARE NOT GENERICS. Zangeneh F; Dolinar R Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083 [No Abstract] [Full Text] [Related]
12. Take this medicine: the legality of prescription incentive schemes. Fanning J; Glover-Thomas N Med Law Rev; 2010; 18(3):417-26. PubMed ID: 20739438 [No Abstract] [Full Text] [Related]
13. European Court of Justice. ECJ 2010/6 Association of the British Pharmaceutical Industry v. Medicines and Healthcare Products Regulatory Agency, 22 April 2010 (C-62/09). Baeyens A; Goffin T Eur J Health Law; 2010 Sep; 17(4):415-9. PubMed ID: 20873523 [No Abstract] [Full Text] [Related]
15. Paying physicians to prescribe generic drugs and follow-on biologics in the United States. Sarpatwari A; Choudhry NK; Avorn J; Kesselheim AS PLoS Med; 2015 Mar; 12(3):e1001802. PubMed ID: 25781468 [TBL] [Abstract][Full Text] [Related]
16. The rise and rise of generic prescribing. Appleby J BMJ; 2015 Oct; 351():h5507. PubMed ID: 26486378 [No Abstract] [Full Text] [Related]
17. Multiple schedule II prescriptions: the final rule. Brushwood DB J Pain Palliat Care Pharmacother; 2008; 22(2):139-43. PubMed ID: 19042838 [TBL] [Abstract][Full Text] [Related]
18. Moves to eliminate 'anticompetitive' practices in the supply of prescription-only veterinary medicines. Vet Rec; 2003 Apr; 152(16):482-4. PubMed ID: 12733556 [No Abstract] [Full Text] [Related]
19. Survey provides insight into prescribing under the cascade. Vet Rec; 2014 May; 174(20):489. PubMed ID: 24832875 [No Abstract] [Full Text] [Related]
20. Taking back your turf: understanding the role of law in medical decision making in opioid management (Part I--overview). Bolen J J Opioid Manag; 2005; 1(3):125-30. PubMed ID: 17315415 [No Abstract] [Full Text] [Related] [Next] [New Search]